Skip to content
Peptidepedia

AOD-9604 Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timelines

AOD-9604 results are modest compared to approved anti-obesity medications. Timelines below are based on clinical trial data and community reports, not guaranteed outcomes.

Weeks 1 to 4: Minimal visible changes. Some users report subtle differences in how their body responds to exercise and diet. No significant weight loss is expected during this period based on available data.

Weeks 4 to 8: In the 12-week Phase IIa trial, treated subjects were on a trajectory that produced an average of 2.6 kg total weight loss by the end of the study. Any changes during this window are likely incremental and may be difficult to distinguish from normal fluctuations in body composition.

Weeks 8 to 12: The end of a standard cycle. The 12-week clinical trial showed an average difference of 1.8 kg between treatment and placebo groups. Users may notice modest reductions in abdominal adiposity if combined with consistent exercise and caloric control.

Beyond 12 weeks: The 24-week Phase IIb trial found no statistically significant difference between treatment and placebo groups, suggesting that any effects may plateau or diminish over longer durations. This is a significant limitation of the available evidence.

Frequently Asked Questions

Early 12-week clinical trials showed modest weight loss (2.6 kg vs. 0.8 kg placebo), but the larger 24-week Phase IIb trial with 536 subjects failed to demonstrate statistically significant fat loss. Drug development was abandoned in 2007. Current evidence does not support AOD-9604 as an effective standalone weight-loss treatment.

Based on clinical trial data, measurable changes in body composition were observed over 12 to 24 weeks of daily use. However, results were modest and inconsistent across studies. Most community reports suggest 8 to 12 weeks as a minimum evaluation period.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
  2. Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449.
  3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15.
  4. Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77.
  5. Kok P, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. J Clin Endocrinol Metab. 2001;86(2):455-459.
  6. Obesity Pharmacotherapy: Current Perspectives and Future Directions. PMC. 2013.
  7. Kwon DR, et al. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426-432.
  8. WADA Statement on Substance AOD-9604. World Anti-Doping Agency.
  9. FDA Pharmacy Compounding Advisory Committee Meeting, December 4, 2024.
  10. PubChem Compound Summary: AOD-9604. CID 71300630.
←Read the full AOD-9604 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”